Home-Based Cardiac Rehabilitation Using a Smart Ring and Telephone Counselling: A Randomized Controlled Trial.

J Korean Med SciSep 14, 2026 (epub)
Clinical ResearchCardiology

Chul Kim, So Myong Jun, Jeong Yeol Yoo et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of home-based cardiac rehabilitation (HB-CR) using a smart ring and telephone counselling in patients with cardiovascular disease. The intervention group showed a significant improvement in peak oxygen consumption compared to the control group, with an estimated mean difference of 2.0 mL/kg/min (95% CI, 0.7-3.3; P = 0.004) after 3 months.

Key findings

  • Peak oxygen consumption improved significantly in the intervention group compared to the control group.
  • Estimated mean difference in peak oxygen consumption was 2.0 mL/kg/min.
  • Statistically significant group-by-time interaction for peak oxygen consumption (P = 0.004).
  • Both groups showed an increase in peak oxygen consumption over time.

Why it matters

The study highlights the potential of home-based cardiac rehabilitation as a viable alternative to traditional center-based programs, particularly for patients facing accessibility challenges. Enhanced monitoring and support can lead to better health outcomes.

Source

PubMed · PMID 42740666

Published in J Korean Med Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.